



1/2

Compound I monotherapy significantly inhibits vascular pathology
(chronic rejection atherosclerosis)
in murine MHCII mismatched cardiac transplant model




FIG. 1

2/2

Compound 1 significantly inhibits chronic rejection vasculopathy in
fully mismatched (MHC I and MHC II disparate)
Mouse cardiac allografts*




FIG. 2